前苏联专利SU1450742A3 Method of producing derivatives of benzoate ethers or 3-oxymorphinane

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans are useful as analgesics or narcotic antagonists and provide enhanced bioavailability of 3-hydroxymorphinans from orally adminstered doses. Relationship to Other Applications This application is a continuation-in-part of copending application Serial No. 627,923, filed July 5, 1984.
公开号:SU1450742A3
申请号:SU853920678
申请日:1985-07-04
公开日:1989-01-07
发明作者:Габриель Шами Элай
申请人:Е.И.Дюпон Де Немур Энд Компани (Фирма)；
IPC主号:

专利说明:

The invention relates to a process for the preparation of new derivatives of benzoate esters of 3-oximorphinanes of the general formula
I /
(I)
where Y is hydrogen or 4-, or 5-alkoxy group with the number of carbon atoms from 1 to 4, X is OR, where R is CO-alkyl St-C
or C -, - C4-alksh1, R - cyclopropylmethyl or cyclobutylmethyl,
R, - OH
R is OH or 0,
which can be used as painkillers or drug antagonists.
The purpose of the invention is the bioavailability of 3-oxymorphinans when administered orally.
The designations used are the following compounds:
nalbuphine: (-) - 17- (cyclobutylmethyl) -4, Sv-epoxymorphinan-3, 6o, 14-three ol or its salt,
naltrek sleep: (-) - 17- (cycloproshh- .metid) -4, 5 / -epoxy-3,14-dioximorphan-6-one or. his salt
naloxone: (-) - 17-apsh-1-4,5o (-epoxy-3,14-dioximorphinan-6-one or its
salt,
buprenorphine; (-) - 17- (cshslopropylmethyl) --- (1,1-dimethylethyl) -4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy- - (/ - methylgb, 14-etenomorphinan-7-methano or its salt. P p and measures 1. Nalbuphin-3- (acetylsapshacylate)
ABOUT
P
(-СНзСО, Y Н).
35 ml of methylene chloride are poured into a round bottom flask and 3.57 g (0.01 mol) of nalbufin is dissolved in it. Then 1.11 g (0.011 mol) of triethylamine is added and the solution is cooled to 0-5 ° C. After that, a solution of 2.18 g (0.011 mol) of acetylsia- lecyloyl chloride is added dropwise to the contents of the flask with vigorous stirring if 25 ml of methylene chloride in a nitrogen atmosphere at 0-5 ° C

0
five
0
five
thirty
about
After the addition is complete, the ice bath is removed and the reaction mixture is stirred for 5 hours at ambient temperature. According to thin layer chromatography (silica gel, a mixture of ethyl acetate and heg.sana in the ratio 3: 1), the desired product is formed with traces of nalbuphine. The reaction mixture is washed with 10% sodium carbonate solution and then in one, dried over sodium sulfate, filtered and evaporated. The solid residue is triturated with ether, filtered and dried in air. The result is 4.6 g of nalbuphin-3- - (acetylsalidylate) with so pl. 165-68 ° C. According to thin-layer chromatography, the target product is formed with R 0.22, containing impurities with E.f 0.01 and 0.09.
The resulting product is subjected to purification using liquid chromatography under pressure in a column with a diameter of 50 mm and a length of 300 mm, filled with silica gel with a grain size of 15-25 microns. The product is dissolved in methylene chloride and poured onto the column. The elution is carried out with a mixture of hexane and acetone in a ratio of 70:30. The result is 3.6 g of the purified product with an mp. 172-173 ° C. There is one spot on the thin-layer chromatogram, R 0.22. .. According to the data of high-performance liquid chromatography, the resulting product has a purity higher than 99%.
Similarly, but with the use of other starting materials, the following compounds can be obtained (Table 1).
Example 15. Naloxone-3- (acetylsalicylate) -hydrochloride (formula I, where R CHiCH CH, R, OH, R O, 45 X 2 -CH5CO. Y H). .
The wire process of example 1, from 10 mmol nalrxone, 4.1 g of naloxone-3- (acetylsalicylate) -hydrochloride are obtained with a mp. 262-263 S.
Etc. and mea 17. Naltrexone-3- (acetyl salicylate) -hydrochloride (formula I, where R, RI HE, R O, X Y H).
The wire process of Example 1, out of 10 mmol of naltrexone, 3.9 g of naltrexone-3-acetylsalicylate-hydro7 is obtained, with a melting point of m. 247-248 C.
In tab. -2 shows the characteristics of the compounds according to examples 15
50
55
and -16, as well as other compounds that can be obtained by the proposed method.
The drugs of the 3-oxymorphinanes of formula (I) in accordance with the invention can be administered in order to relieve pain in a variety of ways by contacting the active component with sensitive centers in the mammalian body. They can be administered by any existing known methods of administering pharmaceutical preparations, either as individual analgesics, or in combination with other therapeutic agents. They may be administered by themselves, however, it is advisable to introduce it together with a pharmaceutically acceptable carrier. The choice of carrier is determined by the route of administration and standard pharmaceutical practice.
The drugs of the proposed method can be administered orally in the form of solid forms, for example, in the form of tablets, capsules, or powder, or in liquid form, for example, in the form of elicires, syrups and suspensions.
Target compounds are Medicines Naloxone, Naltrexone, and Nalbuphine, are marketed. Since the first two of these drugs are drug antagonists, and nalbuphine is both an agonist and antagonist of drugs that is not registered as a drug, such as morphine and other pure drug agonists, the toxicity of these drugs, based on commercial drugs, is .low. Biological testing. The results of the tests indicate that the new compounds of formula (I) according to the proposed method will absorb the bioavailability of 3-oxymorphinans upon oral administration of the composition. Methods
In order to evaluate the effectiveness of the 3-oxymorphinans prod- ucts using the proposed method, experiments were carried out to determine the rate of their hydrolysis in rat human and rat plasma, as well as the bioavailability of 3-oxymorphinans in dogs and rats after oral administration of the predrug. KoHueHT-
o1450742
ten
five
The 3-hydroxy morphinan ration is determined by analytical high-resolution chromatography. Detection is carried out using an electrochemical sensor that responds to the phenolic hydroxyl group (in the 3-position) and, therefore, does not respond to the Premedication with the protected group in this position. Plasma concentration is determined after solvent extraction. Hydrolysis of plasma.
The drug is added in fresh plasma (not more than 24 hours after withdrawal) in such an amount that its concentration is 0.28 µmol, the plasma is maintained at 37 ° C and the rate of drug appearance is determined.
Bioavailability of 3-oxymorphinans when administered orally.
Rats and dogs were injected intravenously and orally with Z-oxhyurfinans and 5 orally predicted in formula (I). As a rule, Preparations are administered in the form of aqueous solutions prepared immediately prior to administration. Individual dogs receive drugs or solid drugs. Plasma is taken and frozen until a concentration of 3-Oxymorphinan is determined. For 1 each animal, the area under the plasma 3-oxyforce-S-minane concentration curve (AUC) is determined. The bioavailability of 3-oximorphinan (F) is calculated by the formula
0
F
AUC
Ro
Do se
AUC w "DoSe Pt
100/0.
F means the amount (%) of the drug transferred to the plasma. Relative bioavailability (RB) is determined by comparing the bioavailability of 3-Oxymorphinan when administered orally with Premedication () with the bioavailability of an orally administered drug ()
B pro
RE
e -i) 0
The results of experiments with nalbuphine.
As shown by experiments on the bioavailability of nalbuphine when administered orally and by the rate of hydrolysis of prediction in plasma in vitro, dogs were closer to humans than rats and monkeys.
five
In tab. 3 shows the results on the bioavailability (%) of nalbuphine when administered orally in various mammals. On the bioavailability of nalbuphine after oral administration of a dog. (5.4%) is closest to all other experimental animals to humans (14%).
Table 4 shows the half-lives in the hydrolysis of nalbuphine-acetylsapicilate as a precursor of nalbuphia in plasma t 1/2 (h) of various mammals. The half-life in the plasma of dogs is closer in magnitude to the half-life in human plasma.
Taking into account the results given in table. 3 and 4, MO5KNO conclude that the most characteristic criterion in the preclinical evaluation of pre-karst is their bioavailability when administered orally in dogs.

权利要求:
Claims (1)
[1]
In tab. Figure 5 shows the relative accuracy (RB) in dogs of various 3-oxymorphinans in prediction using the proposed method. Invention Formula
The method of obtaining benzoate ester derivatives of 3-ox1-morphine of the general formula

0
about t
five
0742
Where
Y
X R R, is Ro hydrogen, from 1 to 4, OR, where
6
4- or atoms
5-alkoxy carbon from
K - CO-alkyl
or C, -C4-alkyl,
cyclopropylmethyl, cyclobutylmethyl,
HE,
HE or 0,
due to the fact that the corresponding 3-oxymorphinan in an aprotic solvent is reacted with an acyl alcohol with an agent of the general formula
and
where Y and X have the indicated meanings in the presence of a base such as triethylamine, N-methylmorpholine, pyridine, sodium carbonate at a temperature of from 0 ° C to room temperature.
Priority signs: from 05.07.84 R - cyclobutylmethyl, R.J - OH;
from 14.05.85 - all other values of the radicals.
Table 1
Gon
SNG
SNS
OH 0 2-W Base 181-182 OH 0 2-CH 3 H 2 HC1-salt 247-248 OH 0 2-W-g Base 225-227
Mammals
Rat2,7 + 0,4
Dogs . 5.4 ± 0.9
Monkey us. 0.9, ± 1.6
1 / Man1 h
20 mg nalbuphine / kg, 4 mg nalbufine / kg, mg as a tablet or solution.
Spreadsheets
Mammals
lat
0.2
2.8
.0,6
6.2
Example
RB in dogs (bioavailability of 3-oxymorphinan when orally administered w 1)
13,929, 5 42.7
71.9.
81.7
115.9
J670.34 (+30.1)
Order 6981/58 Circulation 370 Subscription -polygr. pr-e, Uzhgorod, st. Project, 4
Bioavailability of nalbuphin,% of the administered dose + SE
Nalbuf 1H-acetyl salicyTable 5

类似技术:

公开号 | 公开日 | 专利标题

SU1450742A3|1989-01-07|Method of producing derivatives of benzoate ethers or 3-oxymorphinane

JP6947713B2|2021-10-13|Peripheral opioid receptor antagonists and their use

Zimmerman et al.1994|Discovery of a potent, peripherally selective trans-3, 4-dimethyl-4-| piperidine opioid antagonist for the treatment of gastrointestinal motility disorders

TWI275591B|2007-03-11|Opiod and opioid-like coumpounds and uses thereof

BR112012000569B1|2021-02-02|composition comprising a conjugate of benzoatohydrocodone | and compositions for oral and intravenous administration comprising the same

EP2279735A2|2011-02-02|Compositions comprising crystalline trans-|-delta-9-tetrahydrocannabinol

TWI465450B|2014-12-21|Nalmefene hydrochloride dihydrate

CA2781436C|2018-01-02|Arachidonic acid analogs and methods for analgesic treatment using same

US5750534A|1998-05-12|Nalbuphine esters having long acting analgesic action and method of use

EP0615756B1|2001-06-27|Nalbuphine esters and long-acting pharmaceutical compositions containing them

ES2357250T3|2011-04-20|COMPOSITIONS THAT INCLUDE TRANS - | - DELTA-9-TETRAHIDROCANNABINOL CRISTALINO.

JPWO2007072749A1|2009-05-28|Antitussive

CZ265798A3|1998-11-11|Morphine a dimorphine salts of anionic non-narcotic analgesics of the substituted carboxylic acid type, process of their preparation, their use and pharmaceutical compositions containing thereof

US5298622A|1994-03-29|Spiroindane opiate analogs

US20180057504A1|2018-03-01|6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain

US4261883A|1981-04-14|Novel N-aralkyl enkephalin amide analogs are provided having analgesic and opioid properties

HUT72972A|1996-06-28|Derivatives of benzoilecgonine, ecgonine and ecgonidine as medicines

KR20150109456A|2015-10-01|Protopanoxadiol derivative, preparation method thereof and application thereof

ES2311034T3|2009-02-01|DERIVATIVES OF INDOL AND USE OF THE SAME IN MEDICINES.

US7053096B2|2006-05-30|Compounds having selective hydrolytic potentials

KR100407458B1|2004-03-26|Benzoylecgonine, ecgonine and ecgonidine deriatives

US6271239B1|2001-08-07|Delta opioid receptor-selective benzylidene-substituted morphinans

Frincke et al.1980|The major metabolite of fentanyl in the horse.

US5763456A|1998-06-09|Benzoylecgonine, ecgonine and ecgonidine derivatives

JP2000511916A|2000-09-12|Polyol succinate and pharmaceutical preparation thereof

同族专利:

公开号 | 公开日

IE851683L|1986-01-05|

IL75721D0|1985-11-29|

IE58136B1|1993-07-14|

GR851653B|1985-11-26|

NO852699L|1986-01-06|

EP0170090B1|1989-09-27|

AU4451685A|1986-01-09|

IL75721A|1990-04-29|

SU1508960A3|1989-09-15|

HU193995B|1987-12-28|

EP0170090A1|1986-02-05|

DK160501B|1991-03-18|

NO171209C|1993-02-10|

FI852659A0|1985-07-04|

PT80773B|1987-10-20|

ES544852A0|1987-04-01|

AU578391B2|1988-10-20|

US4668685A|1987-05-26|

PT80773A|1985-08-01|

DK306885D0|1985-07-04|

ES8704443A1|1987-04-01|

HK39790A|1990-06-01|

FI852659L|1986-01-06|

FI83215C|1991-06-10|

HUT40132A|1986-11-28|

DK306885A|1986-01-06|

CA1301150C|1992-05-19|

DK160501C|1991-08-26|

NO171209B|1992-11-02|

NZ212641A|1988-10-28|

DE3573251D1|1989-11-02|

FI83215B|1991-02-28|

MX160445A|1990-03-02|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

DE224197C|

FR3195M|Smith Kline French Lab|Pharmaceutical compositions comprising derivatives of theban.|

US3254088A|1961-03-14|1966-05-31|Lewenstein|Morphine derivative|

US3332950A|1963-03-23|1967-07-25|Endo Lab|14-hydroxydihydronormorphinone derivatives|

IL26896A|1966-01-19|1970-11-30|Endo Lab|14-hydroxynormorphines and 14-hydroxynormorphinones|

GB1097167A|1966-05-31|1967-12-29|Shionogi & Co|3-hydroxy-6-oxo-n-phenethylmorphinan compounds and their production|

CH560194A5|1967-08-25|1975-03-27|Hoffmann La Roche|

US3654280A|1968-03-21|1972-04-04|Shionogi & Co|L-n allylic-3-hydroxy-6-oxomorphinans|

DE2323192A1|1972-05-10|1973-12-13|Endo Lab|INJECTABLE LONG-ACTING ANTAGONIS PREPARATIONS AGAINST NARCOTICS AND DRUGS|

US4161597A|1976-12-20|1979-07-17|Research Corporation|N-alkyl-14-hydroxymorphinans and derivatives|

JPS59186987A|1983-04-06|1984-10-23|Res Inst For Prod Dev|3-benzoylthio-4,5alpha-epoxy-7alpha--hydroxy-1-methylbutyl)-6- methoxy-17-methyl-6,14-endo-ethenomorphinan|US4673679A|1986-05-14|1987-06-16|E. I. Du Pont De Nemours And Company|Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration|

DK107688D0|1988-03-01|1988-03-01|Novo Industri As|CARBAMIC ACID ESTERS OF SUBSTITUTED 7-HYDROXY-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES|

US6702705B1|1988-05-04|2004-03-09|Igen International, Inc.|Prodrugs activated by targeted catalytic proteins|

US6258360B1|1989-05-04|2001-07-10|Igen International, Inc.|Prodrugs activated by targeted catalytic proteins|

DK24089D0|1989-01-20|1989-01-20|Hans Bundgaard|NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS|

AU673335B2|1991-08-05|1996-11-07|Igen, Inc.|Prodrugs activated by targeted catalytic proteins|

US5968551A|1991-12-24|1999-10-19|Purdue Pharma L.P.|Orally administrable opioid formulations having extended duration of effect|

JP2525552B2|1992-01-23|1996-08-21|東レ株式会社|Morphine derivative and pharmaceutical use|

TW372972B|1992-10-23|1999-11-01|Novartis Ag|Antiretroviral acyl compounds|

EP0615756B1|1993-03-15|2001-06-27|National Science Council|Nalbuphine esters and long-acting pharmaceutical compositions containing them|

JP3843456B2|1993-07-23|2006-11-08|東レ株式会社|Morphinan derivatives and pharmaceutical applications|

US5376662A|1993-12-08|1994-12-27|Ockert; David M.|Method of attenuating nerve injury induced pain|

US5869669A|1996-07-26|1999-02-09|Penick Corporation|Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates|

US6225321B1|1997-06-05|2001-05-01|Oliver Yoa-Pu Hu|Long analgesic acting nalbuphine polyester derivative and method of use|

EP1685839B8|1997-12-22|2013-06-26|Euro-Celtique S.A.|Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist|

US6375957B1|1997-12-22|2002-04-23|Euro-Celtique, S.A.|Opioid agonist/opioid antagonist/acetaminophen combinations|

AT233264T|2000-04-27|2003-03-15|Oliver Yoa-Pu Hu|polynalbuphine derivative|

US6569449B1|2000-11-13|2003-05-27|University Of Kentucky Research Foundation|Transdermal delivery of opioid antagonist prodrugs|

WO2002092060A1|2001-05-11|2002-11-21|Endo Pharmaceuticals, Inc.|Abuse-resistant controlled-release opioid dosage form|

US20040033253A1|2002-02-19|2004-02-19|Ihor Shevchuk|Acyl opioid antagonists|

WO2003084520A2|2002-04-05|2003-10-16|Euro-Celtique S.A.|Pharmaceutical preparation containing oxycodone and naloxone|

US20080020028A1|2003-08-20|2008-01-24|Euro-Celtique S.A.|Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent|

US20040202717A1|2003-04-08|2004-10-14|Mehta Atul M.|Abuse-resistant oral dosage forms and method of use thereof|

EA015615B1|2005-01-28|2011-10-31|Еуро-Селтик С.А.|Alcohol resistant dosage forms|

EP1604666A1|2004-06-08|2005-12-14|Euro-Celtique S.A.|Opioids for the treatment of the Chronic Obstructive Pulmonary Disease |

EP1604667A1|2004-06-08|2005-12-14|Euro-Celtique S.A.|Opioids for the treatment of the restless leg syndrome|

US20080045610A1|2004-09-23|2008-02-21|Alexander Michalow|Methods for regulating neurotransmitter systems by inducing counteradaptations|

WO2006034343A2|2004-09-23|2006-03-30|Alexander Michalow|methods for regulating neurotransmitter systems by inducing counteradaptationS|

EP1695700A1|2005-02-28|2006-08-30|Euro-Celtique S.A.|Dosage form containing oxycodone and naloxone|

EP1702558A1|2005-02-28|2006-09-20|Euro-Celtique S.A.|Method and device for the assessment of bowel function|

EP1928881A2|2005-08-19|2008-06-11|Pharmacofore, Inc.|Prodrugs of active agents|

GB0606124D0|2006-03-28|2006-05-03|Reckitt Benckiser Healthcare|Buprenorphine derivatives and uses thereof|

RU2430089C2|2007-03-09|2011-09-27|Грин Кросс Корпорейшн|Orally bioavailable prodrugs of -3-hydroxymorphinan for preventing or treating parkinson's disease|

MX2011000155A|2008-07-07|2011-03-01|Euro Celtique Sa|Use of opioid antagonists for treating urinary retention.|

US9271940B2|2009-03-10|2016-03-01|Purdue Pharma L.P.|Immediate release pharmaceutical compositions comprising oxycodone and naloxone|

JP5442862B2|2009-07-02|2014-03-12|ケムファーム・インコーポレーテッド|Hydrocodone Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates, Prodrugs, Production Methods and Uses|

US10849981B2|2009-07-02|2020-12-01|KemPham, Inc.|Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof|

WO2011008636A1|2009-07-15|2011-01-20|Mallinckrodt Inc.|3-oxy-hydromorphone derivatives|

UA115028C2|2010-11-12|2017-09-11|Сіоногі Енд Ко., Лтд.|Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same|

EP2771002A4|2011-10-26|2015-08-12|Kempharm Inc|Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof|

CA2918004C|2013-07-23|2018-11-20|Euro-Celtique S.A.|A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation|

KR20190049944A|2014-11-25|2019-05-09|켐팜 인코포레이티드|Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone|

US10155771B2|2015-11-04|2018-12-18|Noramco, Inc.|Selective reduction of morphinan alkaloids|

US10799496B2|2018-07-13|2020-10-13|Alkermes Pharma Ireland Limited|Naphthylenyl compounds for long-acting injectable compositions and related methods|

WO2020012245A1|2018-07-13|2020-01-16|Alkermes Pharma Ireland Limited|Thienothiophene-naltrexone prodrugs for long-acting injectable compositions|

US11186585B2|2018-08-17|2021-11-30|Kappa-Pharma LLC|Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates|

US10975099B2|2018-11-05|2021-04-13|Alkermes Pharma Ireland Limited|Thiophene compounds for long-acting injectable compositions and related methods|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

US62792384A| true| 1984-07-05|1984-07-05|

US06/733,464|US4668685A|1984-07-05|1985-05-14|Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists|

[返回顶部]